Loading clinical trials...
Loading clinical trials...
A Randomized Phase II Study of First Cycle Optimization for Regorafenib Treatment Compared to Standard Dose of Regorafenib in Patients With HCC Who Failed Any 1st Line Systemic Treatment and for Whom the Physician is Intending to Treat With Regorafenib
Conditions
Interventions
Regorafenib 40 MG
Locations
9
United States
Banner MD Anderson Cancer Center
Gilbert, Arizona, United States
VA Long Beach Health System
Long Beach, California, United States
Tulane University
New Orleans, Louisiana, United States
Henry Ford Health Systems
Detroit, Michigan, United States
Cancer and Hematology Centers of Western Michigan
Grand Rapids, Michigan, United States
Saint Louis University
St Louis, Missouri, United States
Start Date
January 21, 2021
Primary Completion Date
October 13, 2021
Completion Date
December 10, 2021
Last Updated
December 30, 2021
NCT06066138
NCT06345508
NCT07485114
NCT06811116
NCT04380545
NCT07291076
Lead Sponsor
SC Liver Research Consortium, LLC
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions